GSK PLC GSK shares shed 1.15% to £18.13 Thursday, on what proved to be an all-around positive trading session for the stock ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...

GSK has outperformed both the healthcare sector and S&P 500 this year, which is notable considering the spectre of high ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

CAMP4 will apply its RAP Platform® to generate antisense oligonucleotide candidates, while GSK will lead development and ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...